The Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market report provides current treatment practices, emerging drugs, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market share of the individual therapies, current and forecasted Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market Size from 2018 to 2030 segmented by seven major markets. The Report also covers current Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Overview

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is an uncommon inflammatory disease of small to medium-sized vessels that frequently presents with rapidly progressive glomerulonephritis and renal failure. However, it can affect any organ system.

 

Download free sample copy- https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market

 

List of regions covered in the report

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

List of companies involved in the report

• GSK
• ChemoCentryx/Vifor Pharma
• InflaRx
• Astrazeneca
• And many others

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Types

granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA, formerly Churg-Strauss syndrome).

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Treatment Market

Treatment of AAV follows type- and activity-adapted regimens according to evidence from controlled trials which have been summarized in the EULAR (European League against Rheumatism) recommendations published in 2009.

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Insights

For EGPA, the current approach to disease management is primarily based on reduction of active inflammation and suppression of the immune response through the use of corticosteroids and concomitant immunosuppressive therapy (e.g., methotrexate, azathioprine, and mycophenolate mofetil) and/or cytotoxic agents (e.g. cyclophosphamide). Although the use of these treatments can be effective for establishing remission, patients remain vulnerable to either the complications of the long-term use of these therapies and to the risk of relapse, particularly if the dose of corticosteroid is reduced.

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Forecast

One large randomized noninferiority trial of patients with AAV has found Rituximab (RTX) to be noninferior to cyclophosphamide as induction therapy, including among the patients with renal involvement at enrollment. A randomized controlled trial comparing the effectiveness of daily oral cyclophosphamide versus intravenous pulses suggested that the pulse regimen significantly reduced cumulative exposure and was not associated with any significant difference in time to remission.

Other agents, including tacrolimus, intravenous immunoglobulin (IVIG) and anti-TNF-α compounds such as etanercept and infliximab, have previously been explored in the treatment of AAV, however, the current evidence supporting their use is limited and, in light of the demonstrable efficacy of other agents, are unlikely to be adopted as first-line induction therapy. Nevertheless, there are relatively few trials that have explored the efficacy of these agents in combination therapy.

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report Scope

• The report covers the descriptive overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market.

 

Download free sample copy- https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market

 

Table of Content

1. Key Insights

2. Executive Summary of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

3. Competitive Intelligence Analysis for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

4. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Market Overview at a Glance

5. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Background and Overview

6. Patient Journey

7. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report Highlights

• In the coming years, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Launch of emerging therapies will significantly impact the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/